Hemoglobin >= 8 g/dL, within 2 weeks of randomization
Within 6 weeks prior to randomization: Hemoglobin must be >= 10 g/dL
Hemoglobin > 9 g/dL, obtained within 4 weeks prior to randomization
Hemoglobin >= 10.0 g/dL measured within 28 days prior to randomization
Obtained within 28 days prior randomization: hemoglobin must be >= 8 g/dL
Hemoglobin >= 9.0 g/dL, within 4 weeks of randomization
Hemoglobin >= 10.0 g/dL and no known active bleeding, measured within 28 days prior to administration of study treatment
Within 10 days of treatment initiation: Hemoglobin >= 8 g/dL
Preoperative hemoglobin concentration >= 10 mg/dL within 30 days of registration
Hemoglobin >= 9 g/dL (for treatment phase)
Hemoglobin >= 9.0 g/dL must be met within 28 days of C1D1
Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin) AND
Hemoglobin >= 9.0 gr/dL
Hemoglobin ?8 g/dL (?80 g/L) (superficial tumor dosing only)
Documented within 14 days of registration: Hemoglobin >= 8 g/dL (may be supported)
Hemoglobin >= 8.0 g/dL at least 3 weeks prior to screening unless attributable to disease
Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin)
Hemoglobin > 9 g/dL (standard international [SI] units: 90 g/L)
Hemoglobin >= 9 g/dL, within 16 days of starting therapy
Hemoglobin >= 9.0 g/dL within 14 days prior to first dose of protocol-indicated treatment.
Within 14 days of randomization: Hemoglobin >= 10 g/dL
Within 14 days of the first dose of study drug: Hemoglobin >= 9.0 g/dL
Hemoglobin >= 8.5 g/dL, performed within 14 days prior to day 1 of protocol therapy
Hemoglobin concentration ? 9.0 g/dL.
Within 28 days prior to treatment start: Hemoglobin >= 9 g/dL
Hemoglobin >= 9.0 g / dl obtained =< 14 days prior to study initiation
Obtained within 21 days prior to cycle 1, day 1: hemoglobin >= 10 g/dl
Within 28 days of cycle 1 day 1: Hemoglobin\t>= 8 g/dL
STUDY TREATMENT: Hemoglobin >= 9.0 g/dL within 14 days prior to the first study treatment.
Hemoglobin >= 9.0 g/dL within 90 days prior to randomization
Hemoglobin >= 8 g/dL (may be supported), within 14 days of registration and within 7 days of the start of treatment
Obtained within 14 days of the first study treatment: Hemoglobin > 9 g/dL
Hemoglobin ? 8 g/dL within 14 days of treatment initiation
Hemoglobin > 8 g/dL (may be supported)
Hemoglobin > 8.0 mg/dL within 14 days of treatment initiation
Hemoglobin >= 9.0 g/dL, obtained within 7 days prior to first study treatment
Within 14 days of the first dose of the study drugs: Hemoglobin >= 9 g/dl (treatment allowed).
Hemoglobin ? 8 g/dL within 10 days prior to “on study” status
Within 7 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL (unless due to bone marrow infiltration by tumor, in which case hemoglobin >= 8 g/dL is allowed) and no blood transfusions in the 7 days prior to entry.
Within 28 days prior to enrollment: Hemoglobin >= 9 g/dL
Obtained within 14 days of the first study treatment: Hemoglobin > 9 g/dL
Patient has a hemoglobin value <10 g/dL at Screening
Within 7 days (+ 3 day window) of enrollment: Hemoglobin >= 9.0 g/dL
Within 7 days before the first dose of study treatment: Hemoglobin >= 9 g/dL
Hemoglobin >= 9 g/dL results within 7 days before study drug administration
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): hemoglobin >= 9.0 g/dL
Hemoglobin (Hg) >= 9 g/dl
Hemoglobin >= 9.0 g/dL within 14 days prior to first dose
Obtained within 14 days of randomization: Hemoglobin >= 9.0 g/dL
Determined within 3 weeks of treatment initiation: Hemoglobin >= 8.0 g/dl
Hemoglobin >= 9 g/dL (within 16 days of enrollment)
Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL
Hemoglobin >= 9 g/dl (treatment allowed) within 14 days prior to study entry
Hemoglobin ? 9.0 g/dL within 14 days prior to the first study treatment (cycle 1, day 1)
To be performed within 10 business days prior to day 1: Hemoglobin >= 8.5 g/dL
Hemoglobin >= 8 g/dL within 16 days of treatment initiation
Obtained =< 14 days prior to randomization: Hemoglobin >= 9.0 g/dL
Completed within 60 days of surgery: Hemoglobin ? 9.0 g/dL
Within 14 days of first dose of study drug administration: Hemoglobin >= 9.0g/dl
Hemoglobin >= 10 gr/dL
Hemoglobin < 10 gr/dL
Hemoglobin > 9 g/dL (untransfused)
Must be met within 28 days of C1D1: Hemoglobin >= 9.0 g/dl
Hemoglobin >= 8 g/dL; this value must be obtained within four weeks before protocol entry
1.0 g/dL,
Hemoglobin > 9 g/dL during screening evaluation
Within 14 days prior to randomization: Hemoglobin must be >= 8 g/dL
Within 14 days of first dose of study drug: Hemoglobin >= 9 g/dL
Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL.
Hemoglobin >/= 9 g/dL prior to initial treatment
Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
Heme: Plt Ct ? 100 x 103/µL, ANC ? 1.5 x 103/µL, and Hemoglobin ? 9 g/dL
Hemoglobin >= 8 g/dL within 2 weeks of the initiation of treatment
Hemoglobin must be >= 10 g/dL within 28 days before randomization
If patient will need ribavirin in their regimen then the following inclusion:\r\n* Hemoglobin (Hg) > 12 g/dL for male\r\n* Hg > 11 g/dL for female
Hemoglobin >= 9 g/dL, within 2 weeks of the first dose of study treatment
Hemoglobin >= 10.0 g/dL, measured within 28 days prior to administration of study treatment
Hemoglobin >= 9 g/dl (per manufacturer recommendation)
Hemoglobin >= 11 g/dL within four weeks prior to randomization
For CRC, hemoglobin ?9.0 g/dL
Patients must have a serum erythropoietin level documented before randomization and =< 56 days before day 1 of study treatment; NOTE: hemoglobin must be < 9.5 g/dL at time that serum erythropoietin is drawn
Within 14 days of enrollment: Hemoglobin >= 9.0 g/dL
Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin); AND
Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to first treatment
Patient has screening hemoglobin <10 mg/dL.
Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL
Within 4 weeks of administration of study therapy: Hemoglobin >= 9 g/dL
Hemoglobin > 9.0 g/dL (obtained =< 7 days prior to randomization)
Hemoglobin >= 9.0 g/dL (hemoglobin may be supported by transfusion) obtained =<14 days prior to randomization
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); hemoglobin ? 9.0 g/dL
Hemoglobin >= 9.0 g/dL obtained =< 14 days prior to randomization
Hemoglobin (Hg) >= 9 g/dL
Hemoglobin >= 9.0 g/dL (obtained within 14 days prior to the first study treatment [course 1, day 1])
Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to first treatment
Hemoglobin >= 9.0 mg/ml
Within 14 days prior to first study treatment: Hemoglobin >= 9.0 g/dL
Hemoglobin >= 8.0 g/dL obtained at baseline (day 1 of cycle 1, before study drug administration)
Hemoglobin >= 8 g/dL, within 14 days prior to initiation of study drug
Hemoglobin ? 8 g/dL (80 g/L) within 21 days prior to randomization
Hemoglobin (Hg) >= 9.0 mg/dL
Hemoglobin >= 9.0 g/dL (SI units 90 g/L)
Obtained within 14 days prior to initiation of treatment: Hemoglobin >= 8.0 g/ dL
Hemoglobin >= 9.0 g/dL, obtained within 14 days of the first dose of study drug
Hemoglobin level less than or equal to 11.0 g/dL as assessed by the local laboratory; sample obtained within 7 days prior to randomization (retest in screening is acceptable).
Hemoglobin >= 9.0 g/dL within 90 days before enrollment
Hemoglobin >= 9 g/dL, obtained within 14 days prior to treatment start
Measured within 28 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL
Hemoglobin >= 12 mg/dL for men and >= 11 for women
Hemoglobin ? 8.0 g/dL (? 7.0 g/dL for hematologic malignancy) Renal function
Hemoglobin >= 9.0 g/dL, performed within 10 days of protocol enrollment
